ORKA

About Oruka Therapeutics, Inc. Common Stock (ORKA) Stock

Oruka Therapeutics, Inc. Common Stock (ORKA) closed the 2026-09-18 session at $95.16, down 2.63% versus the previous close (-2.57). The stock opened at $98.18 and traded between $94.83 and $98.29 during that session. Session trading volume was 523K shares. The volume-weighted average price (VWAP) is $95.97.

Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.

Oruka Therapeutics, Inc. Common Stock has a market capitalization of $6.47 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ORKA is listed on the XNAS exchange. The company employs approximately 68 people. Oruka Therapeutics, Inc. Common Stock is headquartered in MENLO PARK, CA. The recorded listing date is 2024-09-03.

On this page you can find market ORKA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.

Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.